# 40 years of CEPARM: transforming amyloidosis related to transthyretin from neglect to recognition

## TL;DR

This paper highlights how CEPARM transformed the neglected disease ATTR amyloidosis into a recognized condition through research and treatment advancements over 40 years.

## Contribution

The paper emphasizes CEPARM's role in advancing liver transplantation, pharmacological therapies, and patient care for ATTR amyloidosis.

## Key findings

- CEPARM significantly improved recognition and management of FAP through research and treatment innovations.
- Liver transplantation and pharmacological therapies developed by CEPARM enhanced patient outcomes.
- The center's holistic approach to patient care addressed ongoing challenges and ethical issues in the field.

## Abstract

Variant transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTRv-CM), formerly known as familial
amyloidotic polyneuropathy
(FAP), is a severe, progressive disorder caused by mutations in the
transthyretin
(
TTR
) gene. Historically, FAP was considered a neglected disease due to its rarity and the limited understanding of its pathophysiology, which led to minimal research funding and few therapeutic options. The present article explores the transformative role of Centro de Paramiloidose Antônio Rodrigues de Mello (CEPARM), established in 1984, in elevating the status of FAP through significant advancements in research and treatment. Although CEPARM was not the sole catalyst for this shift, its contributions in liver transplantation, the development of pharmacological therapies, and holistic patient care have substantially improved the recognition and management of FAP. The article also examines CEPARM's impact on patient care, the ongoing challenges, and ethical considerations within the field.